Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Argatroban

FDA-approved product (injectable, injection), marketed as Argatroban, Argatroban In 0.9% Sodium Chloride, Argatroban In Dextrose and 1 more.

Registered studies
38
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Argatroban
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Recurrent thrombophlebitis
  • Thrombocytopenia
  • Thrombotic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct thrombin inhibitors
FDA pharmacologic class
Anti-coagulant; Direct Thrombin Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

38registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Argatroban in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Argatroban with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO

    NCT07499037 · start 2027-01

    Registered record
    Registry ID
    NCT07499037
    Conditions
    Pneumonia; Heart Failure
    Interventions
    Low anticoagulation dose of argatroban and enoxaparin during ECMO; Standard anticoagulation dose of argatroban and enoxaparin during ECMO
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-01
    Completion
    2029-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Heart Failure
    InterventionLow anticoagulation dose of argatroban and enoxaparin during ECMO; Standard anticoagulation dose of argatroban and enoxaparin during ECMO
    PhasePhase 2
    Registry statusNot yet recruiting

  • HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT

    NCT07302620 · start 2024-12-03

    Registered record
    Registry ID
    NCT07302620
    Conditions
    Thromboembolic Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-12-03
    Completion
    2026-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolic Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

    NCT06442267 · start 2024-07-30

    Registered record
    Registry ID
    NCT06442267
    Conditions
    Respiratory Insufficiency; Circulatory Failure; Thromboembolism; Bleeding
    Interventions
    Enoxaparin Injectable Solution; Argatroban, 1 Mg/mL Intravenous Solution; Unfractionated heparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-07-30
    Completion
    2027-07-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Insufficiency; Circulatory Failure; Thromboembolism; Bleeding
    InterventionEnoxaparin Injectable Solution; Argatroban, 1 Mg/mL Intravenous Solution; Unfractionated heparin
    PhasePhase 4
    Registry statusRecruiting

  • Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.

    NCT06066762 · start 2023-11-01

    Registered record
    Registry ID
    NCT06066762
    Conditions
    Heparin-induced Thrombocytopenia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-11-01
    Completion
    2025-06-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-induced Thrombocytopenia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

    NCT05325346 · start 2022-03-07

    Registered record
    Registry ID
    NCT05325346
    Conditions
    Heparin-induced Thrombocytopenia
    Interventions
    VLX-1005; Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-07
    Completion
    2022-04-14
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-induced Thrombocytopenia
    InterventionVLX-1005; Argatroban
    PhasePhase 1
    Registry statusCompleted

  • The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

    NCT05033964 · start 2021-12-15

    Registered record
    Registry ID
    NCT05033964
    Conditions
    Coronary Artery Disease
    Interventions
    Percutaneous Coronary Intervention with drug eluting stents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12-15
    Completion
    2026-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPercutaneous Coronary Intervention with drug eluting stents
    PhasePhase 2
    Registry statusUnknown

  • Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO

    NCT05226442 · start 2021-12-01

    Registered record
    Registry ID
    NCT05226442
    Conditions
    Extracorporeal Membrane Oxygenation Complication; Anticoagulants and Bleeding Disorders
    Interventions
    Argatroban; Unfractionated heparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-12-01
    Completion
    2024-07-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtracorporeal Membrane Oxygenation Complication; Anticoagulants and Bleeding Disorders
    InterventionArgatroban; Unfractionated heparin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO

    NCT04925167 · start 2021-07-06

    Registered record
    Registry ID
    NCT04925167
    Conditions
    Respiratory Failure
    Interventions
    Argatroban; unfractionated heparin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-07-06
    Completion
    2023-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Failure
    InterventionArgatroban; unfractionated heparin
    PhaseNot applicable
    Registry statusCompleted

  • Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

    NCT04406389 · start 2020-10-13

    Registered record
    Registry ID
    NCT04406389
    Conditions
    COVID-19
    Interventions
    Enoxaparin sodium; Unfractionated heparin; Fondapariniux; Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-10-13
    Completion
    2022-04-21
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionEnoxaparin sodium; Unfractionated heparin; Fondapariniux; Argatroban
    PhasePhase 4
    Registry statusTerminated

  • Argatroban Monitoring in Critically Ill Patients: Evaluation of a Novel Ecarin-based Bedside Test

    NCT04751357 · start 2020-08-01

    Registered record
    Registry ID
    NCT04751357
    Conditions
    Heparin-induced Thrombocytopenia
    Interventions
    ECA-Test (Clot-Pro)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2022-06-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-induced Thrombocytopenia
    InterventionECA-Test (Clot-Pro)
    PhaseNot recorded
    Registry statusUnknown

  • Monitoring Anticoagulation in Patients on ECMO for Severe Lung Failure

    NCT06038682 · start 2020-04-01

    Registered record
    Registry ID
    NCT06038682
    Conditions
    ARDS; COVID-19
    Interventions
    Argatroban Injection; Heparin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2023-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionARDS; COVID-19
    InterventionArgatroban Injection; Heparin
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

    NCT04275180 · start 2020-03-21

    Registered record
    Registry ID
    NCT04275180
    Conditions
    Acute Progressive Ischemic Stroke
    Interventions
    Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-03-21
    Completion
    2023-01-31
    Enrolment
    628

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Progressive Ischemic Stroke
    InterventionArgatroban
    PhasePhase 4
    Registry statusCompleted

  • Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)

    NCT04202549 · start 2019-12-15

    Registered record
    Registry ID
    NCT04202549
    Conditions
    Ischemic Stroke
    Interventions
    intra-arterial cocktail therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-12-15
    Completion
    2022-09-20
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke
    Interventionintra-arterial cocktail therapy
    PhaseNot applicable
    Registry statusCompleted

  • Multi-arm Optimization of Stroke Thrombolysis

    NCT03735979 · start 2019-10-15

    Registered record
    Registry ID
    NCT03735979
    Conditions
    Acute Ischemic Stroke
    Interventions
    Argatroban; Eptifibatide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-15
    Completion
    2024-10-31
    Enrolment
    514

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionArgatroban; Eptifibatide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

    NCT03809481 · start 2019-05-16

    Registered record
    Registry ID
    NCT03809481
    Conditions
    Heparin-induced Thrombocytopenia
    Interventions
    Danaparoid Sodium; Argatroban
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-05-16
    Completion
    2022-06-10
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeparin-induced Thrombocytopenia
    InterventionDanaparoid Sodium; Argatroban
    PhasePhase 3
    Registry statusTerminated